Clover Health CEO says growth and profitability can coexist in Medicare Advantage

As seen on the 24/7 Wall St. homepage on November 4, 2026.

Our results further demonstrate our technology-powered differentiation, and how earlier and better care management, market-leading growth, and increasing profitability can reinforce one another under the right model.

Toy is claiming Clover can grow membership and widen margins at the same time, a combination most Medicare Advantage insurers have abandoned as star ratings tighten and costs climb. For a $2 billion insurer, that claim on the Q3 call is the whole investment case, so the proof has to show up in next quarter's medical cost ratio.

Continue ReadingShow less

Andrew Toy, Clover Health's chief executive, used the company's Q3 2026 earnings call to argue that its technology-driven care management model lets it do something most rivals have stopped attempting: grow its membership base while simultaneously improving profitability. That combination has become rare across the Medicare Advantage industry, where tightening star ratings and rising medical costs have pushed larger insurers to choose one or the other.

Toy's framing centers on the idea that earlier and better care management works as an economic lever, not only as a clinical talking point. The argument is that intervening sooner in a patient's care cycle reduces costly downstream utilization, which in theory allows margins to expand even as the company adds members and absorbs the fixed costs that come with scale.

Sponsored

For a company of Clover Health's size, the entire investment thesis rests on this claim holding up in the numbers. The critical metric to watch in the next quarterly earnings report is the medical cost ratio, which measures what share of premium revenue goes toward paying claims. If that ratio is tightening while membership grows, Toy's case gets meaningfully stronger. If it moves the other way, the Q3 narrative becomes much harder to defend.

The broader Medicare Advantage market provides a punishing backdrop for this bet. Competitors have broadly retreated from aggressive growth targets after underestimating how star rating changes and elevated utilization would compress margins. Clover's willingness to press forward with both levers at once sets it apart, but it also means the company has less room for error than peers that have already pulled back.

Mentioned: CLOV